

Yazen Alnouti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4308656/publications.pdf>

Version: 2024-02-01

60
papers

2,661
citations

236833

25
h-index

189801

50
g-index

61
all docs

61
docs citations

61
times ranked

4001
citing authors

#	ARTICLE	IF	CITATIONS
1	Harmonizing lipidomics: NIST interlaboratory comparison exercise for lipidomics using SRM 1950 "Metabolites in Frozen Human Plasma. <i>Journal of Lipid Research</i> , 2017, 58, 2275-2288.	2.0	312
2	Bile Acid Sulfation: A Pathway of Bile Acid Elimination and Detoxification. <i>Toxicological Sciences</i> , 2009, 108, 225-246.	1.4	304
3	Quantitative-profiling of bile acids and their conjugates in mouse liver, bile, plasma, and urine using LC-MS/MS. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 873, 209-217.	1.2	223
4	Modulation of the intestinal bile acid/farnesoid X receptor/fibroblast growth factor 15 axis improves alcoholic liver disease in mice. <i>Hepatology</i> , 2018, 67, 2150-2166.	3.6	189
5	Quantitative analysis of endogenous compounds. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2016, 128, 426-437.	1.4	170
6	Simultaneous characterization of bile acids and their sulfate metabolites in mouse liver, plasma, bile, and urine using LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 55, 1111-1119.	1.4	110
7	Creation of a long-acting nanoformulated dolutegravir. <i>Nature Communications</i> , 2018, 9, 443.	5.8	101
8	The profile of bile acids and their sulfate metabolites in human urine and serum. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2013, 942-943, 53-62.	1.2	95
9	Species differences in bile acids I. Plasma and urine bile acid composition. <i>Journal of Applied Toxicology</i> , 2018, 38, 1323-1335.	1.4	81
10	Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles. <i>Biomaterials</i> , 2018, 151, 53-65.	5.7	77
11	Impaired synaptic development in a maternal immune activation mouse model of neurodevelopmental disorders. <i>Brain, Behavior, and Immunity</i> , 2015, 50, 249-258.	2.0	71
12	Preclinical Pharmacokinetics and Tissue Distribution of Long-Acting Nanoformulated Antiretroviral Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3110-3120.	1.4	70
13	A year-long extended release nanoformulated cabotegravir prodrug. <i>Nature Materials</i> , 2020, 19, 910-920.	13.3	66
14	Urinary Bile Acids as Biomarkers for Liver Diseases I. Stability of the Baseline Profile in Healthy Subjects. <i>Toxicological Sciences</i> , 2015, 143, 296-307.	1.4	49
15	Mechanisms of gender-specific regulation of mouse sulfotransferases (Sults). <i>Xenobiotica</i> , 2011, 41, 187-197.	0.5	45
16	Development and characterization of a long-acting nanoformulated abacavir prodrug. <i>Nanomedicine</i> , 2016, 11, 1913-1927.	1.7	41
17	Species differences in bile acids II. Bile acid metabolism. <i>Journal of Applied Toxicology</i> , 2018, 38, 1336-1352.	1.4	41
18	Leveraging of Rifampicin-Dosed Cynomolgus Monkeys to Identify Bile Acid 3-O-Sulfate Conjugates as Potential Novel Biomarkers for Organic Anion-Transporting Polypeptides. <i>Drug Metabolism and Disposition</i> , 2017, 45, 721-733.	1.7	38

#	ARTICLE	IF	CITATIONS
19	UPLC-MS/MS quantification of nanoformulated ritonavir, indinavir, atazanavir, and efavirenz in mouse serum and tissues. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2011, 879, 2332-2338.	1.2	33
20	Urinary Bile Acids as Biomarkers for Liver Diseases II. Signature Profiles in Patients. <i>Toxicological Sciences</i> , 2015, 143, 308-318.	1.4	33
21	Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, .	1.4	30
22	Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir. <i>Nature Communications</i> , 2021, 12, 3453.	5.8	29
23	Nod2 deficiency protects mice from cholestatic liver disease by increasing renal excretion of bile acids. <i>Journal of Hepatology</i> , 2014, 60, 1259-1267.	1.8	28
24	Pharmacokinetic and Biodistribution Studies of HPMA Copolymer Conjugates in an Aseptic Implant Loosening Mouse Model. <i>Molecular Pharmaceutics</i> , 2017, 14, 1418-1428.	2.3	26
25	Simultaneous LC-MS/MS analysis of eicosanoids and related metabolites in human serum, sputum and BALF. <i>Biomedical Chromatography</i> , 2018, 32, e4102.	0.8	26
26	Transformation of tenofovir into stable ProTide nanocrystals with long-acting pharmacokinetic profiles. <i>Nature Communications</i> , 2021, 12, 5458.	5.8	26
27	Simultaneous determination of zidovudine and lamivudine from rat plasma, amniotic fluid and tissues by HPLC. <i>Biomedical Chromatography</i> , 2004, 18, 641-647.	0.8	25
28	Assessing the lymphoid tissue bioavailability of antiretrovirals in human primary lymphoid endothelial cells and in mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 2974-2978.	1.3	24
29	A long acting nanoformulated lamivudine ProTide. <i>Biomaterials</i> , 2019, 223, 119476.	5.7	24
30	Creation of a long-acting rilpivirine prodrug nanoformulation. <i>Journal of Controlled Release</i> , 2019, 311-312, 201-211.	4.8	22
31	Pharmacokinetics, Biodistribution, and Toxicity of Folic Acid-Coated Antiretroviral Nanoformulations. <i>Antimicrobial Agents and Chemotherapy</i> , 2014, 58, 7510-7519.	1.4	21
32	Optimizing the preparation and stability of decorated antiretroviral drug nanocrystals. <i>Nanomedicine</i> , 2018, 13, 871-885.	1.7	21
33	Determination of lamivudine in plasma, amniotic fluid, and rat tissues by liquid chromatography. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2004, 803, 279-284.	1.2	20
34	Simultaneous determination of zidovudine and lamivudine from rat tissues by liquid chromatography/tandem mass spectrometry. <i>Rapid Communications in Mass Spectrometry</i> , 2005, 19, 503-508.	0.7	20
35	<p>Synthesis and characterization of a long-acting emtricitabine prodrug nanoformulation</p>. <i>International Journal of Nanomedicine</i> , 2019, Volume 14, 6231-6247.	3.3	16
36	Synthesis of a long acting nanoformulated emtricitabine ProTide. <i>Biomaterials</i> , 2019, 222, 119441.	5.7	15

#	ARTICLE	IF	CITATIONS
37	Increased glycine-amidated hyocholic acid correlates to improved early weight loss after sleeve gastrectomy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2018, 32, 805-812.	1.3	14
38	Synthesis and SAR Studies of 1 <i>H</i> -Pyrrolo[2,3- <i>b</i>]pyridine-2-carboxamides as Phosphodiesterase 4B (PDE4B) Inhibitors. <i>ACS Medicinal Chemistry Letters</i> , 2020, 11, 1848-1854.	1.3	14
39	Simultaneous quantification of intracellular lamivudine and abacavir triphosphate metabolites by LC-MS/MS. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 153, 248-259.	1.4	13
40	The selective PPAR- δ agonist seladelpar reduces ethanol-induced liver disease by restoring gut barrier function and bile acid homeostasis in mice. <i>Translational Research</i> , 2021, 227, 1-14.	2.2	13
41	A combination of Omega-3 PUFAs and COX inhibitors: A novel strategy to manage obesity-linked dyslipidemia and adipose tissue inflammation. <i>Journal of Diabetes and Its Complications</i> , 2020, 34, 107494.	1.2	10
42	Intramuscular and subcutaneous administration of antiretroviral drugs, compared with oral, enhances delivery to lymphoid tissues in BALB/c mice. <i>Journal of Antimicrobial Chemotherapy</i> , 2021, 76, 2651-2658.	1.3	10
43	Simultaneous quantitation of zidovudine and zidovudine monophosphate from plasma, amniotic fluid and tissues by micellar capillary electrophoresis. <i>Biomedical Chromatography</i> , 2004, 18, 523-531.	0.8	8
44	Pharmacokinetic testing of a first-generation cabotegravir prodrug in rhesus macaques. <i>Aids</i> , 2019, 33, 585-588.	1.0	8
45	KVA-D-88, a Novel Preferable Phosphodiesterase 4B Inhibitor, Decreases Cocaine-Mediated Reward Properties <i>in Vivo</i> . <i>ACS Chemical Neuroscience</i> , 2020, 11, 2231-2242.	1.7	8
46	Discovery, synthesis and characterization of a series of (1-alkyl-3-methyl-1 <i>H</i> -pyrazol-5-yl)-2-(5-aryl-2 <i>H</i> -tetrazol-2-yl)acetamides as novel GIRK1/2 potassium channel activators. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 791-796.	1.0	6
47	Direct and indirect quantification of phosphate metabolites of nucleoside analogs in biological samples. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2020, 178, 112902.	1.4	6
48	The Synergistic Effect of an ATP-Competitive Inhibitor of mTOR and Metformin on Pancreatic Tumor Growth. <i>Current Developments in Nutrition</i> , 2020, 4, nzaa131.	0.1	6
49	A combination of dietary N-3 fatty acids and a cyclooxygenase-1 inhibitor attenuates nonalcoholic fatty liver disease in mice. <i>Journal of Nutritional Biochemistry</i> , 2017, 42, 149-159.	1.9	4
50	Head-to-head comparative pharmacokinetic and biodistribution (PK/BD) study of two dexamethasone prodrug nanomedicines on lupus-prone NZB/WF1 mice. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102266.	1.7	4
51	Bile acid indices as biomarkers for liver diseases I: Diagnostic markers. <i>World Journal of Hepatology</i> , 2021, 13, 433-455.	0.8	4
52	Preliminary preclinical study of Chol-DsiRNA polyplexes formed with PLL[30]-PEG[5K] for the RNAi-based therapy of breast cancer. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2021, 33, 102363.	1.7	4
53	Bile acid indices as biomarkers for liver diseases II: The bile acid score survival prognostic model. <i>World Journal of Hepatology</i> , 2021, 13, 543-556.	0.8	3
54	Small-molecule IKK β activation modulator (IKAM) targets MAP3K1 and inhibits pancreatic tumor growth. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, e2115071119.	3.3	3

#	ARTICLE	IF	CITATIONS
55	Analyte recovery in LC-MS/MS bioanalysis: An old issue revisited. <i>Analytica Chimica Acta</i> , 2022, 1198, 339512.	2.6	1
56	Discovery, synthesis and biological characterization of a series of <i>N</i> -(1-(1,1-dioxidothiophen-3-yl)-3-methyl-1 <i>H</i> -pyrazol-5-yl)acetamide ethers as novel GIRK1/2 potassium channel activators. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1366-1373.	1.7	0
57	Substrate specificity of rat Na ⁺ /taurocholate cotransporting polypeptide. <i>FASEB Journal</i> , 2009, 23, 747.5.	0.2	0
58	Characterization of a stable cell line expressing human Na ⁺ /taurocholate cotransporting polypeptide for high throughput screening. <i>FASEB Journal</i> , 2009, 23, 796.12.	0.2	0
59	Direct Comparison of Chol-siRNA Polyplexes and Chol-DsiRNA Polyplexes Targeting STAT3 in a Syngeneic Murine Model of TNBC. <i>Non-coding RNA</i> , 2022, 8, 8.	1.3	0
60	Urinary BA Indices as Prognostic Biomarkers for Complications Associated with Liver Diseases. <i>International Journal of Hepatology</i> , 2022, 2022, 1-17.	0.4	0